Switching of Biological Therapies in Brazilian Patients With Rheumatoid Arthritis

Valim, Juliana Miranda de Lucena; Chaer, Fernanda Gomes Gonçalves; Silveira, Fernanda D'Oliveira Guimarães da; Lima, Verônica Palmiro da Silva e; Souza, Branca Dias Batista de

doi:10.4155/fsoa-2018-0025

Cited by 3 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the Italian LORHEN registry (13) covering 1910 patients among which 1264 patients were treated by rst line bDMARDs (TNFi rst line: 1019, TCZ rst line: 130, Abatacept rst line: 115 patients). In a Brazilian study (15), 94 patients were collected of which 85 (90.4%) patients had received TNFi as rst choice of bDMARDs, in second rank come Abatacept as rst choice therapy then TCZ in four (4%) patients (15). In the Swedish registry, Frisell T et al (7) included 6481 patients who initiated a rst line bDMARDs, most patients started TNFi (n = 5307, 82%), in the non-TNFi group Rituximab was the more prescribed as rst biologic (n = 655, 10% of all rst bDMARD) followed by Abatacept (n = 274) then TCZ (n = 245).…”

Section: Discussionmentioning

confidence: 98%

The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies

Eddaoudi

Rostom

Hmamouchi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment.Methods: Cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized.Results: A total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3rd position with 12.4% (n = 28). The factors associated with the choice of Rituximab as the first line bDMARDs prescribed in univariate analysis were: the insurance type, the positivity of the rheumatoid factor. In multivariate analysis, only the insurance type that remains associated with the choice of Rituximab as the first biological drugs. The Tocilizumab was associated with shorter disease duration and was more prescribed as mono-therapy compared to non Tocilizumab group. TNFi was associated with the insurance type.Conclusion: Our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 98%

The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies

Eddaoudi

Rostom

Hmamouchi³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Seropositivity and the presence of extra-articular involvements are regarded as poor prognostic markers for RA. Previous studies reported different RF and ACPA positivity rates reaching 90% [ 7 , 11 , 27 ]. In the current study, we have determined 80.4 and 73.7% of our cohort were positive for RF and ACPA, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…The erosive disease seen in younger patients is also a significant risk factor for refractoriness to the biological agents [ 31 ]. Previous studies reported the incidence of erosive arthritis in RA populations was ranged up to 86% [ 3 , 5 , 7 , 8 , 27 , 29 , 31 ]. In our study, the incidence was 51.0%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Introduction: Rheumatoid arthritis is a chronic inflammatory disease with different disease activity grades. Several registries have been designed to determine the appropriate regimens of disease-modifying antirheumatic drugs to obtain sustained clinical remission. We examined epidemiological and clinical characteristics of rheumatoid arthritis patients using a clinical registry database (BioSTaR) and analyzed the differences in patients with sustained and switched therapies. Methods: A multicenter, observational crosssectional study for rheumatoid arthritis was

show abstract

“…ADRs are the second leading cause of discontinuing disease-modifying antirheumatic drugs (DMARDs) in RA patients. With up to 27% of RA patients, leading to exacerbated RA symptoms, inflammation, and the potential requirement of expensive medications [ 7 , 8 ]. Consequently, it is essential to identify, address, and prevent ADRs in order to effectively assist rheumatic patients, especially those suffering from RA [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995–2015)

Almutairi,

Inderjeeth,

Preen

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

Background/Objectives Adverse drug reactions (ADRs) can result in morbidity, mortality, and higher healthcare costs. Given the limited information available on ADRs associated with antirheumatic medications, this study aims to analyse and compare ADR reporting for these drugs in the pharmacovigilance datasets of Western Australia (WA) and the United States (US). Methods Therapeutic Goods Administration provided WA pharmacovigilance data of selected antirheumatic drugs to from 1995 to 2015. The proportional reporting ratio (PRR) for WA case reports was compared to corresponding USA pharmacovigilance data by assessing the disproportionality of each ADR. clinically significant or true ADRs were determined using the Evans 2001 criteria (n > 2, chi-square > 4, PRR > 2). Results A total of 232 reports were found in WA, mostly on sixty-nine women aged 45 to 69. Methotrexate, leflunomide, azathioprine, sulfasalazine, and infliximab had the highest reported ADRs, related to gastrointestinal disorders. Patients who used biological agents in WA had 2.7 times the likelihood of reporting true ADRs compared to conventional antirheumatic drugs. The ADR rates in the two datasets were comparable over the study period. Conclusions The PRR values of ADRs were consistent between WA and US databases. Methotrexate and infliximab use were commonly associated with ADR reports in WA females, with incidence rates comparable to the US; while patients using biological agents were more likely to report true ADRs than those on conventional antirheumatic drugs in WA.

show abstract

Switching of Biological Therapies in Brazilian Patients With Rheumatoid Arthritis

Cited by 3 publications

References 26 publications

The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies

The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies

Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis

The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995–2015)

Contact Info

Product

Resources

About